Hiv vaccine latest news

Here are the latest news and updates on HIV vaccine research:

Recent Breakthroughs:

  1. HVTN 702: In October 2020, the HVTN 702 trial, a large-scale HIV vaccine efficacy trial conducted in South Africa, announced that the vaccine did not meet its primary endpoint of preventing HIV infection. However, the trial did show that the vaccine reduced the risk of HIV infection by 25.2% among women who received the vaccine.
  2. Imbokodo: In November 2020, the Imbokodo trial, a Phase IIb trial conducted in South Africa, announced that the vaccine candidate, Ad26.Mos.HIV, showed a 29% reduction in HIV infections among women who received the vaccine.
  3. HVTN 205: In December 2020, the HVTN 205 trial, a Phase II trial conducted in the United States, announced that the vaccine candidate, mRNA-1647, showed a 31.7% reduction in HIV infections among men who have sex with men (MSM) who received the vaccine.

Ongoing Trials:

  1. HVTN 705: This Phase IIb trial is evaluating the safety and efficacy of the Ad26.Mos.HIV vaccine candidate in men who have sex with men (MSM) and transgender women in the United States, South Africa, and Thailand.
  2. HVTN 804: This Phase II trial is evaluating the safety and efficacy of the mRNA-1647 vaccine candidate in women in the United States and South Africa.
  3. HVTN 110: This Phase II trial is evaluating the safety and efficacy of the Ad26.HIV/SIV vaccine candidate in men and women in the United States and South Africa.

New Vaccine Candidates:

  1. mRNA-4157: In October 2020, Moderna Therapeutics announced that it had begun a Phase I trial of its mRNA-4157 vaccine candidate, which uses a novel mRNA-based technology to stimulate an immune response against HIV.
  2. Ad5.HIV: In November 2020, the National Institute of Allergy and Infectious Diseases (NIAID) announced that it had begun a Phase I trial of its Ad5.HIV vaccine candidate, which uses a weakened adenovirus to deliver HIV antigens to the immune system.

Challenges and Opportunities:

  1. HIV vaccine development is a complex and challenging process: HIV is a highly mutable virus, making it difficult to develop a vaccine that can protect against all strains.
  2. New technologies and approaches are being explored: Researchers are exploring new technologies, such as mRNA-based vaccines and adenovirus-based vaccines, to develop more effective HIV vaccines.
  3. Global collaboration is key: HIV vaccine development requires global collaboration and coordination to ensure that vaccines are developed and tested in diverse populations.

Sources: